Polygenic Score (PGS) ID: PGS000057

Predicted Trait
Reported Trait Coronary heart disease
Mapped Trait(s) coronary artery disease (EFO_0001645)
Released in PGS Catalog: Dec. 18, 2019
Download Score FTP directory
Terms and Licenses
PGS obtained from the Catalog should be cited appropriately, and used in accordance with any licensing restrictions set by the authors. See EBI Terms of Use (https://www.ebi.ac.uk/about/terms-of-use/) for additional details.

Score Details

Score Construction
PGS Name CHD57
Variants
Original Genome Build hg19
Number of Variants 57
Development Method
Name Hard thresholding
Parameters Independent variants associated with CHD, with suitable proxies (r2 > 0.8) in the cohorts
PGS Source
PGS Catalog Publication (PGP) ID PGP000042
Citation (link to publication) Natarajan P et al. Circulation (2017)

Contributing Samples

Source of Variant Associations (GWAS)
Study Identifiers Sample Numbers Sample Ancestry
EuropePMC: 26934567
[
  • 42,335 cases
  • , 78,240 controls
]
 European
GWAS Catalog: GCST003116
EuropePMC: 26343387		 11,323 individuals East Asian
GWAS Catalog: GCST003116
EuropePMC: 26343387		 25,557 individuals South Asian
GWAS Catalog: GCST003116
EuropePMC: 26343387		 2,268 individuals Greater Middle Eastern (Middle Eastern, North African or Persian)
GWAS Catalog: GCST003116
EuropePMC: 26343387		 4,095 individuals Hispanic or Latin American
GWAS Catalog: GCST003116
EuropePMC: 26343387		 141,217 individuals European
GWAS Catalog: GCST003116
EuropePMC: 26343387		 3,139 individuals African American or Afro-Caribbean
EuropePMC: 23202125
[
  • 63,746 cases
  • , 130,681 controls
]
 European, South Asian

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance Metric ID
(PPM ID) 		PGS Sample Set ID
(PSS ID) 		Performance Source Trait PGS Effect Sizes
(per SD change) 		PGS Classification Metrics Other Metrics Covariates Included in the Model PGS Performance: Other Relevant Information
PPM000145 PSS000090 PGP000042 Natarajan P et al. (2017) Reported Trait: Coronary artery calcification OR: 1.32 [1.04, 1.68] — OR (highest vs. lowest quintile of PGS): 2.51 [1.08, 5.85] age, sex, diabetes meliitus status, smoking status, LDL cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive medication status, family history of CHD —
PPM000144 PSS000091 PGP000042 Natarajan P et al. (2017) Reported Trait: Coronary heart disease (incident) — — HR (highest vs. lowest quintile of PGS): 1.66 [1.21, 2.29] age, sex, diabetes meliitus status, smoking status, LDL cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive medication status, family history of CHD —
PPM000146 PSS000089 PGP000042 Natarajan P et al. (2017) Reported Trait: Carotid artery plaque burden β: 1.097 [1.022, 1.178] — — age, sex, diabetes meliitus status, smoking status, LDL cholesterol, HDL cholesterol, systolic blood pressure, antihypertensive medication status, family history of CHD —

Evaluated Samples

PGS Sample Set ID
(PSS ID) 		Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS000089 Total carotid plaque burden (mm2) — 4,392 individuals Range = [55.0, 80.0] years NR — BioImage —
PSS000090 Total coronary arterial clacification (CAC) was coded as a a dichotomous outcome variable (CAC>0 versus CAC=0), and quantified by the Agatston method Mean = 15.0 years 1,154 individuals Range = [32.0, 47.0] years NR — CARDIA —
PSS000091 Nonfatal myocardial infarction or death from CHD Mean = 13.5 years
Sd = 2.8 years		 2,440 individuals,
100.0 % Male samples
 Mean = 55.1 years
Sd = 5.5 years		 NR — Participants were all men hypercholesterolemia but without a history of myocardial infarction, allocated to the placebo group